Browsing by Author "Swidan M.M."

Now showing 1 - 2 of 2

I-131 doping of silver nanoparticles platform for tumor theranosis guided drug delivery
(Elsevier B.V., 2018) Sakr T.M.; Khowessah O.M.; Motaleb M.A.; Abd El-Bary A.; El-Kolaly M.T.; Swidan M.M.; Radioactive Isotopes and Generator Department; Hot Labs Center; Egyptian Atomic Energy Authority; PO13759; Cairo; Egypt; Pharmaceutical Chemistry Department; Faculty of Pharmacy; Modern Sciences and Arts University; 6th October City; Egypt; Pharmaceutics and Industrial Pharmacy Department; Faculty of Pharmacy; Cairo University; PO11562; Cairo; Egypt; Labeled Compounds Department; Hot Labs Center; Egyptian Atomic Energy Authority; PO13759; Cairo; Egypt
Nanotechnology may be applied in medicine where the utilization of nanoparticles (?100 nm) for the delivery and targeting of theranostic agents is at the forefront of projects in cancer nano-science. This study points a novel one step synthesis approach to build up polyethylene glycol capped silver nanoparticles doped with I-131 radionuclide (131I-doped Ag-PEG NPs). The formula was prepared with average hydrodynamic size 21 nm, zeta potential � 25 mV, radiolabeling yield 98 � 0.76%, and showed good in-vitro stability in saline and mice serum. The in-vitro cytotoxicity study of cold Ag-PEG NPs formula as a drug carrier vehicle showed no cytotoxic effect on normal cells (WI-38 cells) at a concentration below 3 ?L/104 cells. The in-vivo biodistribution pattern of 131I-doped Ag-PEG NPs in solid tumor bearing mice showed high radioactivity accumulation in tumor tissues with maximum uptake of 35.43 � 1.12 and 63.8 � 1.3% ID/g at 60 and 15 min post intravenous (I.V.) and intratumoral injection (I.T.), respectively. Great potential of T/NT ratios were obtained throughout the experimental time points with maximum ratios 45.23 � 0.65 and 92.46 � 1.02 at 60 and 15 min post I.V. and I.T. injection, respectively. Thus, 131I-doped Ag-PEG NPs formulation could be displayed as a great potential tumor nano-sized theranostic probe. � 2018 Elsevier B.V.
Iron oxide nanoparticulate system as a cornerstone in the effective delivery of Tc-99m radionuclide: a potential molecular imaging probe for tumor diagnosis
(Springer, 2019) Swidan M.M.; Khowessah O.M.; El-Motaleb M.A.; El-Bary A.A.; El-Kolaly M.T.; Sakr T.M.; Labeled Compounds Department; Hot Labs Center; Egyptian Atomic Energy Authority; PO13759; Cairo; Egypt; Pharmaceutics and Industrial Pharmacy Department; Faculty of Pharmacy; Cairo University; PO11562; Cairo; Egypt; Radioactive Isotopes and Generator Department; Hot Labs Center; Egyptian Atomic Energy Authority; PO13759; Cairo; Egypt; Pharmaceutical Chemistry Department; Faculty of Pharmacy; Modern Sciences and Arts University; 6th October City; Egypt
Background: The evolution of nanoparticles has gained prominence as platforms for developing diagnostic and/or therapeutic radiotracers. This study aims to develop a novel technique for fabricating a tumor diagnostic probe based on iron oxide nanoparticles excluding the utilization of chelating ligands. Methods: Tc-99m radionuclide was loaded into magnetic iron oxide nanoparticles platform (MIONPs) by sonication. 99mTc-encapsulated MIONPs were fully characterized concerning particles size, charge, radiochemical purity, encapsulation efficiency, in-vitro stability and cytotoxicity. These merits were biologically evaluated in normal and solid tumor bearing mice via different delivery approaches. Results: 99mTc-encapsulated MIONPs probe was synthesized with average particle size 24.08 7.9nm, hydrodynamic size 52nm, zeta potential -28mV, radiolabeling yield 96 0.83%, high in-vitro physiological stability, and appropriate cytotoxicity behavior. The in-vivo evaluation in solid tumor bearing mice revealed that the maximum tumor radioactivity accumulation (25.39 0.57, 36.40 0.59 and 72.61 0.82%ID/g) was accomplished at 60, 60 and 30min p.i. for intravenous, intravenous with physical magnet targeting and intratumoral delivery, respectively. The optimum T/NT ratios of 57.70, 65.00 and 87.48 were demonstrated at 60min post I.V., I.V. with physical magnet targeting and I.T. delivery, respectively. These chemical and biological characteristics of our prepared nano-probe demonstrate highly advanced merits over the previously reported chelator mediated radiolabeled nano-formulations which reported maximum tumor uptakes in the scope of 3.65 0.19 to 16.21 2.56%ID/g. Conclusion: Stabilized encapsulation of 99mTc radionuclide into MIONPs elucidates a novel strategy for developing an advanced nano-sized radiopharmaceutical for tumor diagnosis. [Figure not available: see fulltext.]. 2019, Springer Nature Switzerland AG.